Yindan Xinnaotong Soft Capsules Obtained The Registration And Marketing Authorization For Traditional Chinese Medicine In Brazil.
Recently, the overseas registration project of Yindan Xinnaotong Soft Capsules organized by Beletalent obtained the Brazilian Traditional Chinese Medicine Registration and Marketing Authorization issued by ANVISA (Brazilian National Health Surveillance Agency), heralding a new chapter in the internationalization of this product.
Yindan Xinnaotong Soft Capsules are a compound preparation developed based on the “two diseases and two guidelines” theory of Miao medicine. It is composed of 8 medicinal herbs: Ginkgo Leaf, Danshen Root, Shortscape Fleabane Herb, Gynoacemmae Herba, Hawthorn Frui,Garlic Bulb, Sanch and l-Borneol. It is mainly used to activate blood, resolve stasis, move qi, relieve pain, promote digestion and resolve stagnation.Chest bi disorder due to qi stagnation and blood stasis, manifested as oppression in the chest, shortness of breath, and palpitations; Angina pectoris in coronary heart disease, hyperlipidaemia，cerebral arteriosclerosis, stroke and sequela of apoplexy with the symptoms described above.
At present, Yindan Xinnaotong Soft Capsules has been approved as the first Chinese medicine second-class protection variety (protected variety number is ZYB2072024003), is the national medical insurance class B variety, the national basic drug species, and the first batch of vaccine drug species collected in the “Chinese Pharmacopoeia”, and won the 17th “China Patent Excellence Award”. It has been listed in the “Science and Technology Competitiveness List of large varieties of Chinese Medicine” for many times, and has been selected in the “Clinical Application Guide of proprietary Chinese Medicine”, “Consensus of Traditional Chinese Medicine Experts on the Diagnosis and Treatment of Coronary Heart Disease Stable Angina Pectoris”, “Guide to Rational Drug Use of Coronary Heart Disease Stable Angina Pectoris Traditional Chinese Medicine Diagnosis and Treatment Guide” and so on.
As the core variety of Guizhou Bailing, Yindan Xinnaotong Soft Capsules sales have maintained steady growth for many years, and it is the mainstream product of Chinese proprietary medicine for cardiovascular and cerebrovascular internal administration. With the improvement of people’s health awareness and the arrival of the aging society, the demand for cardiovascular and cerebrovascular proprietary Chinese medicine market has shown a significant growth trend, and the market prospect of Yindan Xinnaotong Soft Capsules is more promising.
The approval of Yindan Xinnaotong Soft Capsules for traditional Chinese medicine registration and marketing authorization in Brazil not only acknowledges its unique therapeutic value in the domestic cardiovascular and cerebrovascular fields, but also affirms the quality of Guizhou Bailing’s products. This will facilitate the expansion of the product’s presence in international markets and bolster its brand influence.
